Oncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12

Rhea-AI Summary

Oncocyte Corp (Nasdaq: OCX) has announced it will release its third quarter 2024 financial results on Tuesday, November 12, 2024, after U.S. market closes. The company will host a conference call and webcast at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time on the same day. Investors can access the call via toll-free number 800-715-9871 for domestic callers or +1 (646) 307-1963 for international callers, using Conference ID 4153469. A webcast replay will be available on the company's website after the call.

Conference Call and Webcast on Tuesday, November 12, 2024, at 2:00 p.m. PT / 5:00 p.m. ET

IRVINE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, announced today that the company will release its third quarter 2024 financial results on Tuesday, November 12, 2024, after U.S. market closes. The company will also host a conference call and webcast on Tuesday, November 12, 2024, at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and highlights.

Interested parties may access the live call via telephone by dialing toll free 800-715-9871 for domestic callers. Once dialed in, ask to be joined to the Oncocyte Corporation call.

The live webcast of the call may be accessed by visiting the “Events & Presentations” section of the Company’s website at https://investors.oncocyte.com. A replay of the webcast will be available on the Company’s website shortly after the conclusion of the call. 

CONFERENCE CALL DETAILS:
Participant Toll-Free Dial-In Number: (800) 715-9871
Participant Toll Dial-In Number: +1 (646) 307-1963
Conference ID: 4153469

WEBCAST DETAILS: https://events.q4inc.com/attendee/686764682

About Oncocyte
Oncocyte is a diagnostics technology company. The Company’s tests are designed to help provide clarity and confidence to physicians and their patients. VitaGraft™ is a clinical blood-based solid organ transplantation monitoring test. GraftAssure™ is a research use only (RUO) blood-based solid organ transplantation monitoring test. DetermaIO™ is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaCNI™ is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. For more information about Oncocyte, please visit https://oncocyte.com/.

For more information about our products, please visit the following web pages:

VitaGraft Kidney™ - https://oncocyte.com/vitagraft-kidney/
VitaGraft Liver™ - https://oncocyte.com/vitagraft-liver/
GraftAssure™ - https://oncocyte.com/graftassure/
DetermaIO™ - https://oncocyte.com/determa-io/
DetermaCNI™ - https://oncocyte.com/determa-cni/

VitaGraft™, GraftAssure™, DetermaIO™, and DetermaCNI™ are trademarks of Oncocyte Corporation.

CONTACT:
Jeff Ramson
PCG Advisory
(646) 863-6893
jramson@pcgadvisory.com

FAQ

When will Oncocyte (OCX) release Q3 2024 earnings?

Oncocyte will release its Q3 2024 financial results on Tuesday, November 12, 2024, after U.S. market closes.

What time is Oncocyte's (OCX) Q3 2024 earnings call?

Oncocyte's Q3 2024 earnings call is scheduled for Tuesday, November 12, 2024, at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time.

How can I join Oncocyte's (OCX) Q3 2024 earnings call?

You can join by dialing 800-715-9871 (toll-free) for domestic calls or +1 (646) 307-1963 for international calls, using Conference ID 4153469. Alternatively, you can access the webcast through the company's investor relations website.